Drugs that contain Dapagliflozin
1. Drug name - FARXIGA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(3 years from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(7 years from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN103319445B | ASTRAZENECA AB | Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof |
Jun, 2027
(4 years from now) | |
| CN101479287A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773B | ASTRAZENECA AB | Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid |
Jun, 2027
(4 years from now) | |
| CN101479287B | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445A | ASTRAZENECA AB | Sglt2 Inhibitor Crystal Structure And Its Preparation Method |
Jun, 2027
(4 years from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP3045466A1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374B1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374A1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3045466B1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807A1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP3363807B1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP2069374B2 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 6 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(2 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(3 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(5 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(7 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(7 years from now) | |
| US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(17 years from now) | |
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; treatment of type 2 diabetes mellitus in combination with exenatide; reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone; Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.